A six-year-old girl from Stevenage, Hertfordshire, has experienced a remarkable improvement in her vision following gene therapy for a rare genetic eye condition known as Leber’s congenital amaurosis (LCA). Saffie Sandford, who had struggled with her sight since infancy, was treated with Luxturna, a pioneering gene therapy, which has allowed her to regain the ability to see in low-light environments.
:max_bytes(150000):strip_icc():format(jpeg)/Saffie-Sandford-042926-155706dcb8e04c22bf23fb201d5b7f02.jpg)
LCA is an inherited retinal disease that typically results in severe visual impairment, with many affected individuals facing complete blindness by their third decade of life. Saffie’s condition was diagnosed at the age of five after her parents, Lisa and Tam, realised that she had difficulty seeing at night. Lisa recalled the overwhelming emotions that accompanied the diagnosis, stating, “It was a huge shock to us as we’d never heard of the condition or knew that we were carriers.”
From a young age, Saffie’s challenges with visual perception were pronounced. Her mother explained that daily activities became significantly more difficult, necessitating the use of torches for basic tasks such as eating dinner or enjoying colouring sessions. “Life was really hard. She missed out on a lot,” Lisa lamented, illustrating the profound impact the condition had on their family life.
In April 2025, Saffie began her treatment at Great Ormond Street Hospital, where she received a healthy copy of the defective gene in one eye, followed by a second injection in the other eye later that year. Although Lisa initially kept her expectations low regarding the therapy, she expressed her relief at the availability of a treatment through the National Health Service (NHS). “We were grateful when we heard there was a treatment available,” she said.
The results of the procedure exceeded the family’s hopes. Saffie’s vision markedly improved, allowing her to join her peers in activities previously beyond her reach. One memorable occasion came during Halloween, when she enthusiastically participated in trick-or-treating. “She was running down the path in the dark shouting, ‘I can see!’ We were just in floods of tears, the whole family. This has given our little girl her life back,” Lisa recalled.
Consultant ophthalmologist Rob Henderson, who was involved in Saffie’s care, commented on the significance of the treatment. He noted that for the first time, they could objectively demonstrate that gene therapy can enhance visual pathways in young children with rare eye conditions. “Even small improvements in their child’s ability to see the world around them make a profound difference,” he added, highlighting the transformative potential of such therapies for affected families.
Research from Great Ormond Street Hospital and University College London further supports the promise of Luxturna as a means to improve vision. A study involving 15 children aged between 15 months and 12 years revealed that younger patients exhibited more significant benefits from the treatment than their older counterparts. Henderson remarked on the implications of this discovery for children with inherited retinal diseases, reflecting on Saffie’s case as an inspiring example of the therapy’s potential.
Saffie’s current well-being is remarkable, as reflected in her mother’s observations. “She is thriving, and you wouldn’t know she had the condition just by looking at her. The results have been incredible,” Lisa expressed, embodying the hope that gene therapy offers to families facing similar challenges.
As advancements in gene therapy continue to evolve, Saffie Sandford’s story stands as a beacon of hope for others dealing with inherited retinal diseases. With continued research and developments, the future holds promise for numerous children who, like Saffie, strive for a brighter world filled with colour and clarity.